Breakthrough HIV prevention drug raises concerns over access
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Twice-yearly lenacapavir prevented all HIV infections among more than 2,000 young women in a 2024 trial in South Africa and Uganda. WHO recommends it for PrEP, but access is threatened as global HIV funding fell 18% to $7.3bn in 2025.
Continue in the app — vote & join in ➔Source: Al Jazeera English · via ahirlevel.hu